Showing results (91-100 of 255) with videos related to
Sort By:
Pageof 26
Blood|June 25, 2015
Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)Nina D Wagner-Johnston, Brian K Link, Michelle Byrtek, et al.Clinical Immunology (Orlando, Fla.)|January 31, 2012
Syk inhibition with fostamatinib leads to transitional B lymphocyte depletionPaul M Barr, Chungwen Wei, James Roger, et al.Journal of Adolescent and Young Adult Oncology|September 3, 2025
Real World Data Identifies Care Needs in Adolescent and Young Adult Patients with Lymphoma: A Matched Cohort StudyJohn Mariano, Myla Strawderman, Eric Snyder, et al.Leukemia & Lymphoma|October 26, 2020
Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphomaThomas D Rodgers, AnnaLynn M Williams, Andrea Baran, et al.Journal of Geriatric Oncology|March 7, 2026
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailtyPatrick M Reagan, Allison Magnuson, Craig A Portell, et al.Journal of Orthopaedic Surgery (Hong Kong)|September 3, 2010
Predictive factors for recurrence of simple bone cyst of the proximal humerusKar Hao Teoh, Adam C Watts, Yu-Han Chee, et al.American Journal of Hematology|April 29, 2016
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United StatesChadi Nabhan, Xiaolei Zhou, Bann-Mo Day, et al.Blood|September 11, 2004
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicityJonathan W Friedberg, Helen Kim, Mary McCauley, et al.Haematologica|July 3, 2025
Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trialAlexey V Danilov, Hongli Li, Mazyar Shadman, et al.Cancer Medicine|October 5, 2016
Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effectiveRobin M Reid, Andrea Baran, Jonathan W Friedberg, et al.Pageof 26